Insider Buying: ARCA biopharma, Inc. (NASDAQ:ABIO) Major Shareholder Acquires 28,326 Shares of Stock

ARCA biopharma, Inc. (NASDAQ:ABIO) major shareholder Henderson Group Plc Janus acquired 28,326 shares of ARCA biopharma stock in a transaction on Friday, July 5th. The shares were purchased at an average cost of $3.43 per share, for a total transaction of $97,158.18. Following the acquisition, the insider now owns 1,676,903 shares in the company, valued at approximately $5,751,777.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Henderson Group Plc Janus also recently made the following trade(s):

• On Wednesday, July 10th, Henderson Group Plc Janus acquired 55,463 shares of ARCA biopharma stock. The shares were purchased at an average cost of $3.46 per share, for a total transaction of $191,901.98.
• On Monday, July 8th, Henderson Group Plc Janus purchased 47,492 shares of ARCA biopharma stock. The stock was bought at an average cost of $3.46 per share, for a total transaction of $164,322.32.
• On Wednesday, July 3rd, Henderson Group Plc Janus purchased 166,042 shares of ARCA biopharma stock. The stock was bought at an average cost of $3.55 per share, for a total transaction of $589,449.10.

ARCA biopharma Price Performance

Shares of ABIO stock traded up $0.03 during trading hours on Friday, reaching $3.35. The company had a trading volume of 14,055 shares, compared to its average volume of 713,609. The company has a 50 day moving average of $3.43 and a 200 day moving average of $2.54. The firm has a market cap of $48.61 million, a price-to-earnings ratio of -7.98 and a beta of 0.90. ARCA biopharma, Inc. has a 1-year low of $1.56 and a 1-year high of $4.49.

ARCA biopharma (NASDAQ:ABIO) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter.

Institutional Trading of ARCA biopharma

An institutional investor recently bought a new position in ARCA biopharma stock. Cable Car Capital LLC acquired a new stake in ARCA biopharma, Inc. (NASDAQ:ABIO) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 4,000,452 shares of the biopharmaceutical company’s stock, valued at approximately $6,801,000. ARCA biopharma makes up approximately 7.6% of Cable Car Capital LLC’s holdings, making the stock its 4th largest position. Cable Car Capital LLC owned about 27.59% of ARCA biopharma as of its most recent SEC filing. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on ARCA biopharma in a research note on Wednesday, May 22nd. They issued a “sell” rating on the stock.

ARCA biopharma Company Profile

ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.